臨床婦人科産科74巻3号

2020年04月発行

今月の臨床 徹底解説！ 卵巣がんの最新治療―複雑化する治療を整理する

ここが知りたい最新の治療戦略《初回治療》

化学療法先行後の腫瘍減量術（NAC＋IDS）の適応は？

著者： 鈴木嘉穂¹ 寺井義人¹

所属機関： ¹神戸大学医学部産科婦人科

ページ範囲：P.363 - P.368

文献概要

●PDSでR0が可能であれば手術が最優先である．R0が不可能な場合は，組織型がClearあるいはMucinousでなく，PSが不良な患者に対してNAC＋IDSは考慮される．

●NACのレジメンは，conventional TC療法，dose-dense TC療法，weekly TC療法のいずれかを用いる．分子標的薬併用の有効性が期待されている．

●腹腔鏡下生検術は有用性の報告がされており，スコア化することでPDSの可否の判断に用いることができる．臍部腹壁直下に播種病変が大きい場合や癒着が強い症例などは，開腹手術への移行を躊躇しない．

参考文献

1）Winter WE 3rd, et al : Prognostic factors for stage Ⅲ epithelial ovarian cancer : a Gynecologic Oncology Group study. J Clin Oncol 25 : 3621-3627, 2007

2）Winter WE 3rd, et al : Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage Ⅳ epithelial ovarian cancer : a Gynecologic Oncology Group study. J Clin Oncol 26 : 83-89, 2008

3）Chi DS, et al : What is the optimal goal of primary cytoreductive surgery for bulky stage ⅢC epithelial ovarian carcinoma（EOC）? Gynecol Oncol 103 : 559-564, 2006

4）Eisenhauer EL, et al : The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 108 : 276-281, 2008

5）日本婦人科腫瘍学会 : 卵巣癌治療ガイドライン2015年版（日本婦人科腫瘍学会 編）．pp95-97，金原出版，2015

6）Vergote I, et al : Neoadjuvant chemotherapy or primary surgery in stage ⅢC or Ⅳ ovarian cancer. N Engl J Med 363 10 : 943-953, 2010

7）Kehoe S, et al : Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer（CHORUS）: an open-label, randomised, controlled, non-inferiority trial. Lancet 386 : 249-257, 2015

8）Vergote I, et al : Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers : pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol 19 : 1680-1687, 2018

9）Onda T, et al : Comparison of survival between upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomized trial : JCOG0602. J Clin Oncol 36 : #5500, 2018

10）Onda T, et al : Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomized trial : Japan Clinical Oncology Group study JCOG0602. Euro J Cancer 64 : 22-31, 2016

11）Fagotti A, et al : Survival analysis from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load（SCORPION trial）. J Clin Oncol 36 : #5516, 2018

12）Fagotti A, et al : Phase III randomized clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumor load（SCORPION trial）: Final analysis of peri-operative outcome. Euro J Cancer 59 : 22-33, 2016

13）Onda T, et al : Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers : Japan Clinical Oncology Group study JCOG0206. Gynecol Oncol 113 : 57-62, 2009

14）Fagotti A, et al : A multicentric trial（Olympia-MITO 13）on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol 209 : 462.e1-462.e11, 2013

15）Takano M, et al : Clear cell carcinoma of the ovary : Is there a role of histology-specific treatment? J Exp Clin Cancer Res 31 : 53, 2012

16）Shimada M, et al : Clinicopathological characteristics of mucinous carcinoma of the ovary. Gynecol Oncol 113 : 331-334, 2009

17）Rouzier R, et al : Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer : Results from the ANTHALYA trial. Eur J Cancer 70 : 133-142, 2017

18）Komiyama S, et al : Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer : a feasibility study. J Surg Oncol 118 : 687-693, 2018

19）Moore K, et al : Maintenance olaparib in patients with newly Diagnosed advanced ovarian cancer. N Engl J Med 379 : 2495-2505, 2018

20）Ray-Coquard IL, et al : Phase III PAOLA-1/ENGOT-ov25 trial : Olaparib plus bevacizumab（bev） as maintenance therapy in patients（pts）with newly diagnosed, advanced ovarian cancer（OC）treated with platinum-based chemotherapy（Pch）plus bev. An Oncol 30（suppl 5） : V851-V934, 2019

21）Rutten MJ, et al : Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer. J Clin Oncol 35 : 613-621, 2017

22）永井智之，他 : 進行卵巣癌に対する審査腹腔鏡の有用性に対する検討．日産婦内視鏡会誌35 : 92-97, 2019